BRIDGEWATER, New Jersey, October 19, 2018 --- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, announced today V-Go has launched and is now available in Italy through its previously disclosed exclusive distribution agreement with Movi SpA ("Movi").

“We are happy to announce the V-Go Wearable Insulin Delivery device is now available in Italy for patients with type 2 diabetes,” said Valeritas CEO, John Timberlake. “We are excited that the 2 million people in Italy diagnosed with type 2 diabetes now have the option of a simple, affordable, all-in-one insulin delivery system. Valeritas looks forward to V-Go being demonstrated to physicians and patients during the 17th National Congress Italian Society Metabolism Diabetes Obesity (SIMDO) in Palermo, Italy this week.”

"We are proud to be the first European country to officially introduce this new simple and effective device that will help people with Type II diabetes better control their glucose and improve their quality of life," said Movi President, Enrico Piero Bassani.

It is estimated that Italy has over 3 million people with diabetes, 2.0 million of whom are type 2 patients who have been diagnosed and treated. Approximately 56%, or 1.1 million type 2 patients, are not achieving A1c goal of less than 7%.

Through the distribution agreement, Valeritas will retain responsibility for product development, regulatory approval, quality management, and manufacturing while Movi will be responsible for sales, marketing, customer support, and distribution activities in Italy.

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-
bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available at [www.valeritas.com](http://www.valeritas.com) and our Twitter feed @Valeritas_US, [www.twitter.com/Valeritas_US](http://www.twitter.com/Valeritas_US).

**Forward-Looking Statements**

This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Statements or claims made by third parties regarding the efficacy or functionality of V-Go as compared to other products are statements made by such individual and should not be taken as evidence of clinical trial results supporting such statements or claims. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at [www.sec.gov](http://www.sec.gov).

**Investor Contacts:**
Lynn Pieper Lewis or Greg Chodaczek  
Gilmartin Group  
646-924-1769  
ir@valeritas.com

**Media Contact:**  
Kevin Knight  
Knight Marketing Communications, Ltd.  
206-451-4823  
pr@valeritas.com